Dr. Matthew Killeen has been elected to serve on the Sudden Cardiac Arrest Board of Directors. Dr. Killeen specializes in the rapidly-evolving and transformative field of developing new therapies for genetic heart diseases. Having devoted his career to date at the crossroads of research and emerging technologies, he currently serves as a Senior Director at California-based BioMarin Pharmaceutical. In this capacity, he leads new therapeutic R&D for genetic cardiac diseases and works across industry and academia to identify and assess game-changing external programs and technologies with the potential to revolutionize the treatment of inherited heart diseases.
“It is with great pleasure that I announce the election of Matt Killeen, PhD to the Board of Directors of the Sudden Cardiac Arrest Foundation,” said Henry Jampel, MD, Board Chair. “Ever since Dr. Killeen received his PhD in cardiac electrophysiology from Cambridge University, he has devoted himself to the understanding of acquired and genetic arrhythmias that can cause cardiac arrest. In addition to his intellectual interest in sudden cardiac arrest, the board was impressed by his passion for the cause that was apparent during his interview. I know that he will immediately assume a key role in our organization.”